echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Lancet Oncol: The team of Professor Guo Xiang from Sun Yat-sen University Cancer Hospital confirmed through a phase 3 trial that the third-generation platinum drug lobaplatin can effectively treat locally advanced nasopharyngeal carcinoma!

    Lancet Oncol: The team of Professor Guo Xiang from Sun Yat-sen University Cancer Hospital confirmed through a phase 3 trial that the third-generation platinum drug lobaplatin can effectively treat locally advanced nasopharyngeal carcinoma!

    • Last Update: 2021-05-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The National Comprehensive Cancer Network Guidelines recommends the use of cisplatin-based induction chemotherapy plus concurrent radiotherapy and chemotherapy to treat locally advanced nasopharyngeal carcinoma.


    The third-generation platinum drug, Lobaplatin, has shown promising anti-tumor activity in a variety of malignant tumors with low toxicity .


    The third-generation platinum drug, Lobaplatin, has shown promising anti-tumor activity in a variety of malignant tumors with low toxicity

    Professor Guo Xiang, director of the Department of Nasopharyngology, Sun Yat-sen University Cancer Hospital, and his colleagues led a team to carry out an open-label, non-inferiority randomized controlled phase 3 clinical trial in 5 hospitals in China, aiming to evaluate the use of lobaplatin as a Basic induction chemotherapy + concurrent chemoradiation vs.


    Lancet Lancet Oncology Lancet Oncology

    The trial recruited patients with nasopharyngeal carcinoma of stage III-IVB who were 18-60 years old who had not been treated before, and required Karnofsky performance status score ≥ 70 points, and good blood, liver and kidney function.


    From June 7, 2013 to June 16, 2015, after evaluating 515 patients, 502 were recruited into the group: 252 were assigned to the lobaplatin group and 250 were assigned to the cisplatin group.


    Prognosis of the intention-to-treat population

    Prognosis of the intention-to-treat population

    After a median follow-up of 75.


    The 5-year progression-free survival rates of the lobaplatin group and cisplatin group were 75% and 75.


    In the intention-to-treat population, 63 (25%) of 252 patients in the lobaplatin group and 250 patients in the cisplatin group each achieved progression-free survival events; in the protocol-treated population, there were 246 patients in the lobaplatin group 62 (25%) and 58 of the 237 patients in the cisplatin group (25%) achieved progression-free survival events.


    Adverse events

    Adverse events

    The most common grade 3-4 adverse events were mucositis (lobaplatin group vs cisplatin group: 41% vs 40%), leukopenia (16% vs 23%), and neutropenia (10% vs 24 %).


    In summary, the efficacy of lobaplatin-based induction chemotherapy combined with concurrent chemoradiotherapy for patients with locally advanced nasopharyngeal carcinoma is not inferior to that of cisplatin-based treatment, and the side effects are smaller .


    Lobaplatin-based induction chemotherapy combined with concurrent radiotherapy is not inferior to cisplatin-based treatment for patients with locally advanced nasopharyngeal cancer, and the toxic side effects are smaller.


    Original source:

    Xing Lv, et al.


    org/10.
    1016/S1470-2045(21)00075-9" target="_blank" rel="noopener">Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.